Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +23.33%
#4 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +22.84%
#5 Victoria VR Victoria VR +21.15%
#6 Nockchain Nockchain +18.95%
#7 Bedrock Bedrock +17.00%
#8 Versatize Coin Versatize Coin +12.50%
#9 Perle Perle +12.25%
#10 Velvet Velvet +12.00%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Amniotics AB (publ) Amniotics AB (publ)

Amniotics AB (publ)

AMNI
Rank in Stocks #37511
Amniotics AB (publ) specializes in the creation, manufacturing, and... Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Share Price
$0.00060315
Last synced: 2024-09-27
Market Cap
$1.65M
Change (1 day)
19.64%
Change (1 year)
0.00%
Country
SE
Trade Amniotics AB (publ) (AMNI)

Category

Healthcare
P/B ratio for Amniotics AB (publ) (AMNI)
P/B ratio as of August 2026 TTM: 0.98
According to Amniotics AB (publ) latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.98. At the end of 2022 the company had a P/B ratio of 43.73.
P/B ratio history for Amniotics AB (publ) from 2018 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.98 -40.17%
2023 1.63 -96.28%
2022 43.73 263.99%
2021 12.01 -34.02%
2020 18.21 -69.40%
2019 59.51 -75.80%
2018 245.87 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 550.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 540.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 254.92%
BE